525 related articles for article (PubMed ID: 26413978)
21. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
[TBL] [Abstract][Full Text] [Related]
22. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
[TBL] [Abstract][Full Text] [Related]
23. c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers.
La Rosa S; Bernasconi B; Vanoli A; Sciarra A; Notohara K; Albarello L; Casnedi S; Billo P; Zhang L; Tibiletti MG; Sessa F
Virchows Arch; 2018 Oct; 473(4):435-441. PubMed ID: 29721608
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease.
Viúdez A; De Jesus-Acosta A; Carvalho FL; Vera R; Martín-Algarra S; Ramírez N
Crit Rev Oncol Hematol; 2016 May; 101():193-206. PubMed ID: 27021395
[TBL] [Abstract][Full Text] [Related]
26. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract][Full Text] [Related]
27. The dilemma of "indeterminate" interpretations of pancreatic neuroendocrine tumors on fine needle aspiration.
Ahmed A; VandenBussche CJ; Ali SZ; Olson MT
Diagn Cytopathol; 2016 Jan; 44(1):10-3. PubMed ID: 26402138
[TBL] [Abstract][Full Text] [Related]
28. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
[TBL] [Abstract][Full Text] [Related]
29. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
30. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Navale P; Chatterjee D; Itani M; Trikalinos NA
Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
[TBL] [Abstract][Full Text] [Related]
31. Future Directions in the Biology of Neuroendocrine Tumors.
Halperin DM; Dasari A; Yao JC
Pancreas; 2016 Jul; 45(6):783-5. PubMed ID: 27295529
[TBL] [Abstract][Full Text] [Related]
32. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
33. Genes involved in neuroendocrine tumor biology.
Hofsli E
Pituitary; 2006; 9(3):165-78. PubMed ID: 17001466
[TBL] [Abstract][Full Text] [Related]
34. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract][Full Text] [Related]
35. The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors.
Batukbhai BDO; De Jesus-Acosta A
Pancreas; 2019 Jan; 48(1):9-21. PubMed ID: 30531241
[TBL] [Abstract][Full Text] [Related]
36. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
[TBL] [Abstract][Full Text] [Related]
37. Animal models of spontaneous pancreatic neuroendocrine tumors.
Yu R
Mol Cell Endocrinol; 2016 Feb; 421():60-7. PubMed ID: 26261055
[TBL] [Abstract][Full Text] [Related]
38. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
Chatani PD; Agarwal SK; Sadowski SM
Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
[TBL] [Abstract][Full Text] [Related]
39. Targeting pancreatic expressed PAX genes for the treatment of diabetes mellitus and pancreatic neuroendocrine tumors.
Martin-Montalvo A; Lorenzo PI; López-Noriega L; Gauthier BR
Expert Opin Ther Targets; 2017 Jan; 21(1):77-89. PubMed ID: 27841034
[TBL] [Abstract][Full Text] [Related]
40. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
Cives M; Partelli S; Palmirotta R; Lovero D; Mandriani B; Quaresmini D; Pelle' E; Andreasi V; Castelli P; Strosberg J; Zamboni G; Falconi M; Silvestris F
Sci Rep; 2019 Dec; 9(1):18614. PubMed ID: 31819132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]